Literature DB >> 28205683

Cardiovascular Complications and Short-term Mortality Risk in Community-Acquired Pneumonia.

Francesco Violi1, Roberto Cangemi1, Marco Falcone2, Gloria Taliani3, Filippo Pieralli4, Vieri Vannucchi4, Carlo Nozzoli4, Mario Venditti2, Julio A Chirinos5, Vicente F Corrales-Medina6,7.   

Abstract

BACKGROUND.: Previous reports suggest that community-acquired pneumonia (CAP) is associated with an enhanced risk of cardiovascular complications. However, a contemporary and comprehensive characterization of this association is lacking. METHODS.: In this multicenter study, 1182 patients hospitalized for CAP were prospectively followed for up to 30 days after their hospitalization for this infection. Study endpoints included myocardial infarction, new or worsening heart failure, atrial fibrillation, stroke, deep venous thrombosis, cardiovascular death, and total mortality. RESULTS.: Three hundred eighty (32.2%) patients experienced intrahospital cardiovascular events (CVEs) including 281 (23.8%) with heart failure, 109 (9.2%) with atrial fibrillation, 89 (8%) with myocardial infarction, 11 (0.9%) with ischemic stroke, and 1 (0.1%) with deep venous thrombosis; 28 patients (2.4%) died for cardiovascular causes. Multivariable Cox regression analysis showed that intrahospital Pneumonia Severity Index (PSI) class (hazard ratio [HR], 2.45, P = .027; HR, 4.23, P < .001; HR, 5.96, P < .001, for classes III, IV, and V vs II, respectively), age (HR, 1.02, P = .001), and preexisting heart failure (HR, 1.85, P < .001) independently predicted CVEs. One hundred three (8.7%) patients died by day 30 postadmission. Thirty-day mortality was significantly higher in patients who developed CVEs compared with those who did not (17.6% vs 4.5%, P < .001). Multivariable Cox regression analysis showed that intrahospital CVEs (HR, 5.49, P < .001) independently predicted 30-day mortality (after adjustment for age, PSI score, and preexisting comorbid conditions). CONCLUSIONS.: CVEs, mainly those confined to the heart, complicate the course of almost one-third of patients hospitalized for CAP. More importantly, the occurrence of CVEs is associated with a 5-fold increase in CAP-associated 30-day mortality.
© The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  cardiovascular events; mortality.; pneumonia

Mesh:

Year:  2017        PMID: 28205683     DOI: 10.1093/cid/cix164

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  45 in total

1.  A Hypothesis-Generating Study of the Combination of Aspirin plus Macrolides in Patients with Severe Community-Acquired Pneumonia.

Authors:  Marco Falcone; Alessandro Russo; Yuichiro Shindo; Alessio Farcomeni; Filippo Pieralli; Roberto Cangemi; Jinliang Liu; Jingyan Xia; Junya Okumura; Masahiro Sano; Christopher Jones; Vieri Vannucchi; Massimo Mancone; Scott Micek; Feng Xu; Francesco Violi; Marin Kollef
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

2.  Sodium Content of Intravenous Antibiotic Preparations.

Authors:  Nina Wang; Phuong Khanh Nguyen; Christine U Pham; Ethan A Smith; Brian Kim; Matthew Bidwell Goetz; Christopher J Graber
Journal:  Open Forum Infect Dis       Date:  2019-12-17       Impact factor: 3.835

3.  A Composite of Functional Status and Pneumonia Severity Index Improves the Prediction of Pneumonia Mortality in Older Patients.

Authors:  Francisco Sanz; María Morales-Suárez-Varela; Estrella Fernández; Luis Force; María José Pérez-Lozano; Vicente Martín; Mikel Egurrola; Jesús Castilla; Jenaro Astray; Diana Toledo; Ángela Domínguez
Journal:  J Gen Intern Med       Date:  2018-01-04       Impact factor: 5.128

Review 4.  [Atrial fibrillation in patients with sepsis and non-cardiac infections].

Authors:  Benjamin Rath; Philipp Niehues; Patrick Leitz; Lars Eckardt
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2019-08-08

5.  Risk factors, thromboembolic events, and clinical course of New-Onset Atrial Fibrillation among COVID-19 hospitalized patients: A multicenter cross-sectional analysis in Iran.

Authors:  Fatemeh Sadat Rahimi; Siamak Afaghi; Farzad Esmaeili Tarki; Hossein Salehi Omran; Mohammad Hossein Nasirpour
Journal:  Health Sci Rep       Date:  2022-10-17

6.  Effect of cefoperazone sulbactam sodium combined with meropenem on the immune function in the treatment of neonatal pneumonia caused by multidrug-resistant bacteria.

Authors:  Mingjing Lin; Shuxia Zhu; Haimei Weng; Yi Zhu
Journal:  Am J Transl Res       Date:  2021-06-15       Impact factor: 4.060

7.  Endotoxinemia Accelerates Atherosclerosis Through Electrostatic Charge-Mediated Monocyte Adhesion.

Authors:  Ariane Schumski; Almudena Ortega-Gómez; Kanin Wichapong; Carla Winter; Patricia Lemnitzer; Joana R Viola; Mayra Pinilla-Vera; Eduardo Folco; Victor Solis-Mezarino; Moritz Völker-Albert; Sanne L Maas; Chang Pan; Laura Perez Olivares; Janine Winter; Tilman Hackeng; Mikael C I Karlsson; Tanja Zeller; Axel Imhof; Rebecca M Baron; Gerry A F Nicolaes; Peter Libby; Lars Maegdefessel; Frits Kamp; Martin Benoit; Yvonne Döring; Oliver Soehnlein
Journal:  Circulation       Date:  2020-11-10       Impact factor: 29.690

8.  Effect of corticosteroids on myocardial injury among patients hospitalized for community-acquired pneumonia: rationale and study design. The colosseum trial.

Authors:  Francesco Violi; Camilla Calvieri; Roberto Cangemi
Journal:  Intern Emerg Med       Date:  2019-05-31       Impact factor: 3.397

9.  Population-based incidence and mortality of community-acquired pneumonia in Germany.

Authors:  Christian Theilacker; Ralf Sprenger; Friedhelm Leverkus; Jochen Walker; Dennis Häckl; Christof von Eiff; Julia Schiffner-Rohe
Journal:  PLoS One       Date:  2021-06-15       Impact factor: 3.240

Review 10.  Multifaceted Role of Pneumolysin in the Pathogenesis of Myocardial Injury in Community-Acquired Pneumonia.

Authors:  Ronald Anderson; Jan G Nel; Charles Feldman
Journal:  Int J Mol Sci       Date:  2018-04-11       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.